Compare Fox Corp Class A (FOXA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs State Street SPDR S&P Biotech ETF — how do they compare? Fox Corp Class A trades at $56.63 (market cap $22.28B), while State Street SPDR S&P Biotech ETF trades at $153.42. The key difference: Fox Corp Class A pays a 1% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Fox Corp Class A nearer its low. Which is the better fit depends on your goals.
| FOXA | XBI | |
|---|---|---|
Market Cap | $22.28B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $76.11 | $164.28 |
52-Week Low | $48.79 | $85.16 |
Enterprise Value | $26.25B | — |
Dividend Yield | 1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOXA) trades at $55.94, up 1.95% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 14.73 and net income margin of 10.56%, supported by $3.32B in operating cash flow for 2025. Recent news highlights the strategic $22B Roku acquisition, positioning Fox in the competitive streaming landscape.
The outlook is mixed: analyst consensus targets $67.80 (21% upside) with equal buy/hold ratings, but technicals and 2026 cash flow projections signal caution. Key risks include integration challenges from the Roku deal and advertising market volatility. The stock presents a value opportunity if execution risks are managed.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
